Welcome to our inaugural immuno-oncology symposium
Immunotherapy is a huge and still-emerging area within oncology, which is having a significant impact on the way patients with certain malignancies are being treated. Within recent weeks, the American Society of Clinical Oncology named cancer immunotherapy as their clinical Advance of the Year for a second consecutive year, highlighting its continuing importance in changing the face of cancer care.
At the end of June, Oncology Central is hosting a free 2-day online educational symposium, chaired by Professor Angus Dalgleish (St George’s, University of London) aimed at delivering oncology professionals key updates in this field, discussing how practices are changing and what continually emerging data mean for an individual’s own practice. This online symposium will be CME-accredited.
As stated by ASCO there is a,
“high-level of need for clinical education in a field where all aspects of care are fundamentally different from traditional therapies.”
In a series of talks and discussions delivered over two consecutive afternoons by key opinion leaders, we aim to review the current status of immunotherapy in the clinic, while also covering key areas such as rational combinations of immunotherapies with other therapies and management of therapy-related toxicities. We’ll also look at optimization of these therapies; looking into the need for better biomarkers of response, discussing resistance and also asking what is next for immuno-oncology.
Professor Dalgleish was appointed as foundation chair of oncology at St George’s, University of London in 1991. He graduated MBBS at University College, London, in 1974, having done an intercalated BSc in anatomy with Professor J Z Young, FRS. After training as a general physician and specialist medical oncologist he joined Professor Robin Weiss, then head of the Institute of Cancer Research as a clinical research fellow in 1984. His project was on human retroviruses and he was a co-discoverer of the fact that HIV used CD4 as a receptor and senior author of the paper that first linked HIV infection to slim disease in East Africa.
In 1987 he became a Medical Research Council clinical research fellow at the Northwick Park Clinical Research Centre. Here he continued his work on HIV pathogenesis and became part of an EU group focused on the correlates of immune protection. During this time, the association with the induction of immune activation and disease was shown to be absolute, correlating with the observations in chimpanzees.
Professor Dalgliesh was awarded the Joshua Lederberg Prize in 2012.
Day 1 – Wednesday 21st June 2017
14:00-14:10 – Welcome
14:15-14:45 – Update on the current status of immunotherapy in clinical practice
Speaker: Susan Slovin, Memorial Sloan Kettering Cancer Center (NY, USA)
Dr. Slovin is Attending Physician and Member in the Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and Professor of Medicine, Department of Medicine at Joan and Sanford I. Weill Medical College of Cornell University.
14:55-15:25 – Adoptive cell therapy
Speaker: Robert Hawkins, University of Manchester (UK)
Robert Hawkins is Cancer Research UK Professor at the University of Manchester and Christie Hospital. In addition to clinical training he was an MRC Research Fellow with Dr Greg Winter and Dr Cesar Milstein at the MRC laboratory of Molecular Biology in Cambridge. His PhD was in antibody engineering and as a Cancer Research UK Senior Clinical Fellow he developed translational research interests in antibody based gene therapy. He was first appointed as a consultant in Cambridge in 1995 and then became Professor of Oncology at the University of Bristol in 1996. In 1998 he moved to the Christie Hospital to become Professor and Director of Medical Oncology.
15:35-16:05 – Biomarkers for immunotherapy: an illusion or a reality?
Speaker: Marc S. Ernstoff, Roswell Park Cancer Institute (NH, USA)
Over the past 35 years, Marc has focused his clinical research in expanding our understanding or the immunobiology of human cancer and the development of new immune therapies for renal cell carcinoma, melanoma and glioblastoma multiforme. He did his cancer immunology and immunotherapy training in the clinical research and laboratory program of John M. Kirkwood while at Yale University and continued his work in translational immunotherapy at Yale (1984-86), the University of Pittsburgh (2986-1991), Geisel School of Medicine (1991-2014), and the Cleveland Clinic (2014-2016). In 2016, Marc became the Chair of the Department of Medicine and Senior Vice President of Clinical Unvestigation at Roswell Park Cancer Institute.
16:15-16:45 – Immunotherapy Strategies to Turn Cold Tumors Hot
Speaker: James Gulley MD PhD, National Cancer Institute (MD, USA)
Dr. James Gulley, MD, PhD, is Chief, Genitourinary Malignancies Branch; Head of Immunotherapy Section; Director, Medical Oncology Service, National Cancer Institute (NCI). Dr. James Gulley is an internationally recognized expert in cancer immunotherapy with a strong interest in prostate cancer. Since 1998 he has authored and run a variety of clinical trials at the NCI. These innovative investigator initiated studies involve the use of cancer vaccines and other immunostimulatory agents, and the combination of immunotherapy with other treatment strategies. In particular, he has played a central role in the clinical development of a prostate cancer vaccine (Prostvac), created in the NCI, and serves as the principal investigator on an international Phase III randomized clinical trial of this vaccine. He is also the coordinating principal investigator of an international trial of an anti-PDL1 antibody (avelumab) and another international study of anti-PDL1 / TGF-beta Trap (M7824). Areas of Expertise are immunotherapy, therapeutic cancer vaccines, immune checkpoint inhibitors, prostate cancer, clinical trials, combining immunotherapy with other therapies.
16:45-16:50 – Conclusion
Day 2 – Thursday 22nd June 2017
14:00-14:10 – Welcome to Day 2
14:15-14:45 – Chemotherapy and radiotherapy – exploring the synergy with immunotherapy
Speaker: Ravi Madan, National Cancer Institute (MD, USA)
Dr. Madan is the clinical director of the Genitourinary Malignancies Branch. His clinical research is focused on immune stimulating therapies and prostate cancer. Specifically, Dr. Madan’s clinical trials are designed to develop a better understanding of how immune stimulating therapies can improve clinical outcomes and be combined with other therapies. In addition to investigating emerging therapeutics in all stages of prostate cancer, Dr. Madan is exploring immunotherapy treatment strategies in rare tumors such as medullary thyroid cancer.
14:55-15:25 – Management of immunotherapy-related toxicities
Speaker: Hossein Borghaei, Fox Chase Cancer Center (PA, USA)
Hossein Borghaei is the Chief of thoracic medical oncology at Fox Chase Cancer Center. Since completing his fellowship training at Fox Chase, he has been involved in a number of clinical trials aimed at developing new antibody based and immunotherapies for patients with lung cancer.
In addition to his clinical practice and participation in immunotherapy based clinical trials, Borghaei is the PI of a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs with the aim of bringing these approaches to the clinic.
15:35-16:05 – Resistance to immunotherapy in colon cancer
Speaker: Subbaya Subramanian, University of Minnesota (MN, USA)
16:15-16:40 – Personalizing immunotherapy – the development of new biomarkers for predicting response
Speaker: Roy S. Herbst, Yale University (CT, USA)
Dr. Herbst has led development of several targeted agents for non-small cell lung cancer (NSCLC). He co-led the BATTLE-1 and BATTLE-2 trials. His widely published work has been translated from preclinical to clinical settings in multiple studies and focuses on immunotherapy angiogenesis, EGFR/VEGFR inhibition in NSCLC and targeting KRAS-activated pathways.
Herbst is Principal Investigator (PI) for the Yale SPORE in Lung Cancer and a PI for the AACR/ Stand Up to Cancer Dream Team. He is vice chair for developmental therapeutics for Southwestern Oncology Group’s (SWOG) Lung Committee, principal investigator of the SWOG 0819 trial, and steering committee chair for the Lung Master Protocol.
16:40-16:45 – Closing remarks
If you are looking for an economical way to effectively promote your company or organization to oncology professionals the sponsorship opportunities at our Oncology Central Symposium are just what you need. These opportunities are on a first-come, first-served basis.
Other benefits include:
- Access to oncology professionals via our website
- Direct networking opportunities with delegates
- Marketing and brand exposure with minimum hassle
- Premium booth space in the online Exhibition Hall
Want to exhibit? Request our ‘sponsorship opportunities’ packRequest pack